Xu Song

358 Datong Road
Pudong, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The Active Components of Traditional Chinese Medicines Regulate the Multi-Target Signaling Pathways of Metabolic Dysfunction-Associated Fatty Liver Disease.

The Active Components of Traditional Chinese Medicines Regulate the Multi-Target Signaling Pathways of Metabolic Dysfunction-Associated Fatty Liver Disease.

Journal: Drug design, development and therapy

Published: December 26, 2024

Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.

Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.

Journal: Cancer letters

Published: January 06, 2024

Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma.

Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma.

Journal: BMC medical genomics

Published: August 15, 2023

ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment.

ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment.

Journal: Oncology reports

Published: August 03, 2022

[Corrigendum] ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune micro-environment.

[Corrigendum] ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune micro-environment.

Journal: Oncology reports

Published: August 03, 2022

GBP2 serves as a novel prognostic biomarker and potential immune microenvironment indicator in renal cell carcinoma.

GBP2 serves as a novel prognostic biomarker and potential immune microenvironment indicator in renal cell carcinoma.

Journal: Molecular carcinogenesis

Published: March 14, 2022

USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1.

USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1.

Journal: Cancer cell international

Published: May 05, 2021

Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.

Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.

Journal: BMC cancer

Published: April 08, 2021

Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis.

Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis.

Journal: International journal of biological sciences

Published: April 21, 2020

KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.

KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.

Journal: International journal of clinical and experimental pathology

Published: June 26, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026